GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

GAMMAGARD LIQUID for Patients with Primary Immunodeficiency (PI)

Would help from a trained professional give your patients peace of mind?

GAMMAGARD LIQUID can help you and your patients feel at ease with a supervised and trusted PI treatment experience. Patients have the option to receive their intravenous immune globulin (IVIG) or subcutaneous IG (SCIG) treatment at an infusion center, in a physician’s office, or at home, administered by a qualified healthcare professional.1


The close monitoring of patients' experiences when receiving IVIG therapy from their HCP in a preferred setting provides patients with the confidence they need in managing their PI, as well as the assurance that they are on a path to better health.

An older woman smiling while standing outdoors.

Nancy: 65 years old and takes IVIG1*†

  • Prefers professional administration— being under a nurse’s care gives her comfort
  • Wants to work with her healthcare provider (HCP) to find an IG product with an established tolerability profile
  • Prefers to be infused every month
A man in his 20s smiling while standing outdoors.

Steve: 43 years old with weekly SCIG treatments

  • Seeks supervised check-ins
  • Struggles with his weekly self-administered SCIG infusions
  • Would like to switch to monthly IVIG for the added monitoring and interaction with his HCP
A young boy smiling while standing outdoors.

Conor: 13 years old and has not yet used IG

  • He and his mother are seeking education and resources, which allow him to ask questions and access educational materials
  • Conor and his mother prefer that Conor receives his PI care and IVIG treatment at an infusion clinic

*Limited information is available for the use of GAMMAGARD LIQUID in patients older than 65 years. GAMMAGARD LIQUID was evaluated in two PI studies (1 for IVIG administration and 1 for SCIG administration) with a total of 8 patients older than 65. No differences in safety or efficacy were observed for this age group. Monitor patients who are at an increased risk for developing renal failure or thrombotic events. Infuse at the minimum IV infusion rate practicable. Do not exceed the recommended dose.

Hypothetical patient type. Once clinical considerations have been evaluated, patient preferences should be considered.

Patient considerations

GAMMAGARD LIQUID IVIG administration may be appropriate for patients with PI who:

  • Look for reassurance and HCP support while receiving treatment
  • Trust their physician and nurses to administer their IG treatment and handle their care

Patients may prefer IVIG administration for:

  • Peace of mind from receiving care from trained HCPs
  • Supervised check-ins at each infusion, helping to monitor adherence
  • Flexibility to administer at home or in the physician’s office with nurse assistance
Patient talking to her doctor.
Primary Immunodeficiency icon.

What are the warning signs of PI?

Review diagnosis details
IVIG bag icon.

GAMMAGARD LIQUID offers a treatment with a proven history of clinical use for patients with PI1

Clinical trial data